Business
Investors in drugmaker Mesoblast sweat on crucial capital raising – Sydney Morning Herald
The stem cell giant says it needs cash from its existing partnerships to ‘continue as a going concern’.
The ability of the group to continue as a going concern and realise its assets and discharge its liabilities in the normal course of business are dependent on cash inflows from successfully completing the private placement, as well as from existing strategic and financing partnerships, the auditors report said.
Analysts at Bell Potter noted last month that Mesoblasts balance sheet could come under pressure in the 2022 financial year if there were any hiccups with agreements and payments from partners…
-
Noosa News23 hours agoUnlawful wounding charges, Caloundra – Sunshine Coast
-
Business15 hours agoThis artificial intelligence (AI) and “Magnificent Seven” stock will be the next company to surpass a $3 trillion market cap by the end of 2025
-
General17 hours agoFootballers and movie stars: PM’s Shanghai tourism push
-
General14 hours ago‘Hidden and radical’ power of First Nations women unlocked in big hART’s Punkaliyarra project